Featured Research

from universities, journals, and other organizations

MRSA infection with heteroresistance (hVISA) linked to high mortality, study finds

Date:
September 12, 2010
Source:
Henry Ford Health System
Summary:
A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a new study. Researchers found that patients who contracted a MRSA infection with heteroresistance, called hVISA, stayed in the hospital longer, were more likely to have the infection return after 90 days, and were twice as likely to die from it after 90 days than patients who do not have hVISA.

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study.

Researchers found that patients who contracted a MRSA infection with heteroresistance, called hVISA, stayed in the hospital longer, were more likely to have the infection return after 90 days, and were twice as likely to die from it after 90 days than patients who do not have hVISA.

The study is being presented at the 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston.

"Based on our findings, we recommend that hospitals consider routine testing for hVISA," says Katherine Reyes, M.D., a Henry Ford Hospital Internal Medicine physician and the study's lead author. "It remains controversial how differently we will manage these patients upfront. Close follow-up on these patients to make sure their infection is resolved or controlled may save lives."

MRSA, or Methicillin-resistant Staphylococcus aureus, is a bacterium that is resistant to common antibiotics like penicillin. It can cause skin, bloodstream and surgical wound infections and pneumonia. The majority of infections occur among patients in hospitals or other health care settings, though a growing number of infections are being acquired by otherwise healthy people outside those settings.

MRSA strains can be resistant to many drugs, though they are typically susceptible to the antibiotic vancomycin. MRSA infections are often treated with vancomycin administered intravenously.

The study followed 521 patients with MRSA bloodstream infections who were admitted between January 2006 to September 2009 to Henry Ford, an 805-bed tertiary care hospital, education and research complex in Detroit. These infections were screened for heteroresistance, and 19 hVISA cases were identified.

Dr. Reyes and researchers then compared characteristics and outcomes of the 19 hVISA patients against 19 non-hVISA patients, eliminating such factors as age, source of infection and level of sickness. The results:

  • Six hVISA patients died within 30 days compared to three non-hVISA patients.
  • Twelve hVISA patients died within 90 days compared to six non-hVISA patients.
  • Five hVISA patients saw their infection return after 90 days compared to zero for non-hVISA patients.
  • hVISA patients stayed on average four more days in the hospital than non-hVISA patients.
  • hVISA patients were more likely to have received vancomycin in the past.

The study was funded by Henry Ford Hospital's Division of Infectious Diseases.


Story Source:

The above story is based on materials provided by Henry Ford Health System. Note: Materials may be edited for content and length.


Cite This Page:

Henry Ford Health System. "MRSA infection with heteroresistance (hVISA) linked to high mortality, study finds." ScienceDaily. ScienceDaily, 12 September 2010. <www.sciencedaily.com/releases/2010/09/100912151556.htm>.
Henry Ford Health System. (2010, September 12). MRSA infection with heteroresistance (hVISA) linked to high mortality, study finds. ScienceDaily. Retrieved September 20, 2014 from www.sciencedaily.com/releases/2010/09/100912151556.htm
Henry Ford Health System. "MRSA infection with heteroresistance (hVISA) linked to high mortality, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/09/100912151556.htm (accessed September 20, 2014).

Share This



More Health & Medicine News

Saturday, September 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com
How The 'Angelina Jolie Effect' Increased Cancer Screenings

How The 'Angelina Jolie Effect' Increased Cancer Screenings

Newsy (Sep. 19, 2014) Angelina's Jolie's decision to undergo a preventative mastectomy in 2013 inspired many women to seek early screenings for the disease. Video provided by Newsy
Powered by NewsLook.com
The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins